Picard Medical prices $5m offering to clear debt and fund operations
Picard Medical, the NYSE American-listed parent of SynCardia Systems, has priced a $5 million "reasonable best efforts" offering, selling 16.7 million shares of common stock alongside two tranches of warrants at a combined price of $0.30 per share. The transaction is expected to close on or about 6 May 2026, subject to customary conditions.
WestPark Capital acted as sole placement agent. The offering is structured under a Form S-1 registration statement declared effective by the Securities and Exchange Commission on 4 May 2026.
The deal
Investors received Series A Common Warrants, exercisable immediately and expiring after five years, and Series B Common Warrants, also exercisable immediately but expiring after 24 months. Both warrant series carry an exercise price of $0.35 per share — a modest premium to the $0.30 offering price. Pre-funded warrants with an exercise price of $0.0001 were also made available as an alternative to direct share purchase, a structure commonly used when institutional buyers need to manage beneficial ownership thresholds. Holders are capped at 4.99% beneficial ownership on exercise, with an optional 9.99% ceiling elected prior to issuance.
Alongside the primary raise, Picard is exchanging existing warrants covering 7 million shares — previously exercisable at $2.675 — for new warrants on 10 million shares at the reduced $0.35 exercise price. The exchange removes forced-exercise clauses and broad-based anti-dilution price protection provisions from the legacy instruments, which simplifies the company's capital structure but also eliminates downside protections that prior warrant holders had negotiated.
Net proceeds are earmarked first for redemption payments on a senior secured note and working capital loans, with any remaining balance directed to general corporate purposes. The sequencing indicates near-term debt obligations are the immediate constraint on the business.
Market context
The $0.30 share price underscores the financial pressure facing Picard Medical. For a company whose subsidiary, SynCardia, holds a distinctive regulatory position — the only commercially available total artificial heart approved by both the FDA and Health Canada, with more than 2,100 implants across 27 countries — the valuation gap between clinical asset quality and equity market capitalisation is notable.
Total artificial heart technology occupies a narrow but critical niche within the mechanical circulatory support market. Competing approaches include left ventricular assist devices, which address a broader patient population but do not replace both ventricles, leaving the biventricular failure segment — SynCardia's core territory — with limited commercial alternatives. Abbott's HeartMate and Medtronic's HVAD (now discontinued) have dominated the LVAD market, but the TAH space remains largely uncontested at a commercial level.
The medical devices sector has seen renewed investor interest in heart failure technologies following a series of positive trial readouts, but small-cap companies in the space continue to face steep capital-raising hurdles. Picard's ability to convert its regulatory moat into sustainable commercial revenue will be the central question for investors watching this transaction closely.
Picard Medical did not provide revenue figures, procedure volumes, or an updated commercial outlook in the release accompanying the pricing announcement.